Endometrial Endometrioid Adenocarcinoma Clinical Trial
Official title:
Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas
To evaluate the efficacy of sentinel lymph node policy in patients with intermediate-risk endometrial carcinomas
Surgical assessment for staging of endometrial carcinoma during primary surgery remains one
of the most varied practices worldwide, as it may include no nodal assessment, sentinel node
mapping, and complete pelvic and aortic lymphadenectomy up to the renal vessels. Since
lymphadenectomy is significantly associated with longer operating time, higher surgical
costs, greater rate of infection, as well as the occurrence of lymphocysts and lymphedema,
gynecologists agree that pelvic and aortic lymphadenectomy should be routinely performed in
high-risk patients (grade 3, deep myometrial invasion, type 2 cancer). However, whether
lymphadenectomy is required in patients with endometrioid endometrial cancers of grade 1 or 2
and with less than 50% myometrial invasion is controversial. Then, the investigators
conducted this prospective cohort study to investigate the efficacy of sentinel lymph node
policy in patients with intermediate-risk endometrial carcinomas (grade 1 or 2, < 50%
myometrial invasion, and a tumor diameter ≥ 2 cm) as well as their outcomes.
Surgery should be performed within a maximum of 4 weeks from the patient's first
consultation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02728258 -
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05112601 -
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03914612 -
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
|
Phase 3 | |
| Completed |
NCT04972682 -
[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer
|
N/A | |
| Recruiting |
NCT03422198 -
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
|
Phase 3 | |
| Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT02020707 -
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
|
Phase 1 | |
| Recruiting |
NCT05950464 -
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
|
Phase 1 | |
| Recruiting |
NCT04049227 -
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
|
Early Phase 1 | |
| Active, not recruiting |
NCT04214067 -
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
|
Phase 3 | |
| Completed |
NCT00478426 -
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
|
Phase 2 |